Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Frailᵃ male patients with prostate cancer who will start treatment with enzalutamide within label~* Age at least 18 years~* Patient who are able and willing to give written informed consent prior to screening~* Patients from whom it is possible to collect blood samples~* Patients who are willing to answer the questionnaires and test~* Life expectancy of \> 6 months~* Capable of understanding and answering Dutch tests and questionnaires, as determined by the investigator~ᵃ Frail is defined as:~* a score on the comprehensive G8 assessment with cut-off ≤14 points and~* score ≥grade 1 for Central Nervous Disorders according to the Common Toxicity Criteria Adverse Event (CTCAE) criteria, of one of the following: Fatigue, Concentration impairment, cognitive disturbance, amnesia, depressed level of consciousness, memory impairment, hypersomnia.~Exclusion Criteria:~* change in dose of opioids/sedatives/benzodiazepines during last 2 weeks before study)~* Use of psychostimulants such as methylphenidate within 1 week of start of study~* Diagnosed with medical conditions that affect cognition: Dementia, Alzheimer disease, Parkinson's disease, psychiatric disorders that affect cognition other than depression or anxiety complaints related to the disease~* Active infection or other comorbidities that may contribute to REDOSE, February 2019 Page 7 of 53 fatigue or cognition change within 4 weeks of study entry~* Clinical relevant anaemia~* MoCa score \<20~* Hypersensitivity to the active substance or to any of the excipients.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- reference (normal) dose (Type: ACTIVE_COMPARATOR): Normal dose of enzalutamide (160mg once daily)
- test (reduced) dose (Type: EXPERIMENTAL): Reduced dose of enzalutamide (120mg once daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).